title: Will gene therapy trump factor treatment in hemophilia?
abstract: Hemophilia treatment is entering a new phase, with the exciting possibility of gene therapy promising a cure. Novel gene transfer strategies are being considered for patients with inhibitors.Improvement of factor-replacement therapy is being aggressively pursued with long-acting factor concentrates, many of which are in clinical trials. Whether gene therapy will be safe and cost effective to eventually supersede factor-replacement therapy is yet to be determined. It is hoped that with the profusion of clinical trial programs in hemophilia care, it will eventually provide affordable treatment to many patients who currently cannot access adequate treatment in the developing countries.
authors: Centre for Haemostasis & Thrombosis, Guy's & St Thomas' NHS Foundation Trust, St Thomas' Hospital, London, UK. savita.rangarajan@gstt.nhs.uk
authors: Savita
authors: S
authors: Rangarajan
authors: Louis
authors: L
authors: Aledort
mesh_terms: D005169:Factor VIII / Q000627:therapeutic use*; D015316:Genetic Therapy / Q000379:methods*; D006467:Hemophilia A / Q000188:drug therapy* / Q000235:genetics / Q000628:therapy*; D006801:Humans
chemical_list: D005169:Factor VIII